Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
19 04 2022
19 04 2022
Historique:
received:
26
11
2021
accepted:
22
02
2022
revised:
16
02
2022
entrez:
20
4
2022
pubmed:
21
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m
Identifiants
pubmed: 35440099
doi: 10.1038/s41408-022-00659-9
pii: 10.1038/s41408-022-00659-9
pmc: PMC9018764
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Br J Cancer. 2018 Apr;118(7):1013-1019
pubmed: 29527008
Eur J Cancer. 2011 Jul;47(11):1606-15
pubmed: 21354783
Haematologica. 2004 May;89(5):626-8
pubmed: 15136236
Int J Cancer. 2019 Jul 15;145(2):347-359
pubmed: 30614529
Adv Hematol. 2021 Jan 18;2021:6615684
pubmed: 33531904
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2285-91
pubmed: 17119059
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Blood. 2011 Nov 24;118(22):5872-82
pubmed: 21908434
Skeletal Radiol. 2016 Sep;45(9):1277-83
pubmed: 27344672
Cancer Causes Control. 1994 Sep;5(5):479-83
pubmed: 7999970
Am J Epidemiol. 2004 Feb 1;159(3):259-68
pubmed: 14742286
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Biometrics. 1983 Mar;39(1):173-84
pubmed: 6871346
Leukemia. 2014 Jul;28(7):1537-42
pubmed: 24441287
Bone Marrow Transplant. 2014 Aug;49(8):1009-15
pubmed: 24820216
Blood. 2006 Feb 1;107(3):904-6
pubmed: 16210333
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040690
Cancer Causes Control. 2001 Feb;12(2):117-25
pubmed: 11246840
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Blood. 2010 Aug 19;116(7):1056-9
pubmed: 20421448
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Blood. 2014 Jan 16;123(3):338-45
pubmed: 24222331
Lancet. 1998 Mar 28;351(9107):934-9
pubmed: 9734939
Blood. 1992 Apr 1;79(7):1817-22
pubmed: 1558973
Oncology (Williston Park). 2011 Jun;25(7):578-86
pubmed: 21888255
Blood Adv. 2017 Nov 01;1(24):2186-2192
pubmed: 29296866
Obesity (Silver Spring). 2017 Aug;25(8):1317-1320
pubmed: 28602036
Leukemia. 2010 Jun;24(6):1121-7
pubmed: 20410922
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1474-8
pubmed: 17627013
Epidemiology. 2005 Sep;16(5):691-4
pubmed: 16135948
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
JNCI Cancer Spectr. 2019 Jun 24;3(3):pkz044
pubmed: 31448358